‘Digoxin conundrum – Time for validation?’
Indian Heart Journal, 2021 Despite no incontrovertible data, Digoxin use has been demonised. As a consequence, a lot of patients, stable on Digoxin, have been taken off it and offered alternative drugs.
O.P. Yadava
doaj +1 more source
Digoxin and Amiodarone on the Risk of Ischemic Stroke in Atrial Fibrillation: An Observational Study
Frontiers in Pharmacology, 2018 Purpose: The present study compared the risk of ischemic stroke in atrial fibrillation (AF) patients receiving digoxin and amiodarone.Methods: A retrospective cohort study was conducted using the longitudinal population-based database of Taiwan’s ...
Kuan-Cheng Lai +13 more
doaj +1 more source
The effect of digoxin on renal function in patients with heart failure
BMC Nephrology, 2021 Introduction Digoxin is used in patients with chronic heart failure (CHF) who remain symptomatic despite optimal medical treatment. Impaired renal function is commonly associated with CHF.
Parin Shah +5 more
doaj +1 more source
Association is not causation: treatment effects cannot be estimated from observational data in heart failure [PDF]
, 2018 Aims: Treatment ‘effects’ are often inferred from non-randomized and observational studies. These studies have inherent biases and limitations, which may make therapeutic inferences based on their results unreliable.
Campbell, Ross T. +4 more
core +1 more source
Older patients' prescriptions screening in the community pharmacy: development of the Ghent Older People's Prescriptions community Pharmacy Screening (GheOP3S) tool [PDF]
, 2015 Background: Ageing of the population often leads to polypharmacy. Consequently, potentially inappropriate prescribing (PIP) becomes more frequent. Systematic screening for PIP in older patients in primary care could yield a large improvement in health ...
Boussery, Koen +5 more
core +2 more sources
Effects of sacubitril/valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) according to background therapy [PDF]
, 2016 Background—In the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure), the angiotensin receptor neprilysin inhibitor sacubitril/valsartan was more effective than the ...
Gong, Jianjian +11 more
core +2 more sources
Digoxin and Heart Failure: Are We Clear Yet?
Cardiovascular Innovations and Applications, 2017 The Digoxin Investigation Group trial has multiple flaws in the trial design for the findings to be universally applicable. Digoxin in low serum concentrations (0.5–0.9 ng/mL) has been shown to decrease mortality in heart failure patients.
Amit Gupta, Melissa Dakkak, Alan Miller
doaj +1 more source
Mihai Gheorghiade, MD-Life and Concepts [PDF]
, 2018 How do you capture an idea, shape it, and then bring it into the world? Of his many talents, this ability was a fundamental characteristic of Mihai Gheorghiade.
Butler, Javed +3 more
core +1 more source
Recognize and Treatment of Digitalis Intoxication
Majalah Kardiologi Indonesia, 2013 Background: Digitalis is the oldest compound in cardiovascular medicine that continues to be used in contemporary clinical practice. It is one of the most frequently prescribed medications and has historically been implicated as one of the most common ...
Dewi H Suprobo +3 more
doaj +1 more source
Digoxin Suppresses Tumor Malignancy through Inhibiting Multiple Src-Related Signaling Pathways in Non-Small Cell Lung Cancer. [PDF]
PLoS ONE, 2015 Non-small cell lung cancer is the predominant type of lung cancer, resulting in high mortality worldwide. Digoxin, a cardiac glycoside, has recently been suggested to be a novel chemotherapeutic agent.
Sheng-Yi Lin +7 more
doaj +1 more source